1 850

Cited 13 times in

The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with Type 2 diabetes.

 J. S. Nam  ;  J. Y. Nam  ;  J. S. Yoo  ;  M. Cho  ;  J. S. Park  ;  C. W. Ahn  ;  B. S. Cha  ;  E. J. Lee  ;  S. K. Lim  ;  K. R. Kim  ;  H. C. Lee 
 DIABETIC MEDICINE, Vol.27(1) : 30-36, 2010 
Journal Title
Issue Date
Adipokines/metabolism* ; Adult ; Aged ; Body Fat Distribution ; Body Mass Index ; DiabetesMellitus,Type2/drug therapy ; DiabetesMellitus,Type2/metabolism* ; DiabetesMellitus,Type2/physiopathology ; Female ; Humans ; Hypoglycemic Agents/metabolism* ; Hypoglycemic Agents/therapeutic use ; InsulinResistance/physiology* ; Male ; Middle Aged ; Muscle, Skeletal/drug effects ; Muscle, Skeletal/metabolism* ; Muscle, Skeletal/physiopathology ; Thiazolidinediones/metabolism* ; Thiazolidinediones/therapeutic use
adiponectin ; insulin resistance ; Type 2 diabetes ; visceral fat
AIMS: We examined the effect of rosiglitazone on insulin sensitivity, abdominal fat and mid-thigh intramuscular fat distribution, and plasma concentrations of adipocytokines in patients with Type 2 diabetes.

METHODS: Rosiglitazone was administered at a daily dose of 4 mg to 42 Type 2 diabetes patients [age 32-70 years, body mass index (BMI) 17.5-32.6 kg/m(2), 15 women, 27 men] for 12 weeks. Various anthropometric and metabolic profiles, plasma adiponectin, leptin, and resistin levels were measured, and insulin resistance was calculated from the short insulin tolerance test. Body fat composition was assessed by computed tomography.

RESULTS: Twelve weeks' rosiglitazone treatment resulted in improved insulin resistance despite increases in body weight and BMI. There was a significant decrease in abdominal visceral adipose tissue area (145 +/- 65.6 vs. 129 +/- 73.1 cm(2), P = 0.049). Mid-thigh low-density muscle area (TLDMA) increased from 23 +/- 9.6 to 26 +/- 8.2 cm(2) (P = 0.009). There were significant changes in plasma adipocytokines, but they were not significantly correlated with changes in insulin resistance.

CONCLUSIONS: Rosiglitazone treatment resulted in an improvement of insulin responsiveness in Type 2 diabetic subjects, which was associated with the redistribution of visceral and subcutaneous adipose tissue, an increase in TLDMA, and changes in serum adipocytokine levels. Further studies are needed to elucidate the insulin sensitizing mechanism of rosiglitazone on peripheral skeletal muscles.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Kyung Rae(김경래)
Nam, Ji Sun(남지선) ORCID logo https://orcid.org/0000-0001-8655-5258
Park, Jong Suk(박종숙) ORCID logo https://orcid.org/0000-0002-5385-1373
Ahn, Chul Woo(안철우) ORCID logo https://orcid.org/0000-0003-3733-7486
Yoo, Jeong Seon(유정선)
Lee, Eun Jig(이은직) ORCID logo https://orcid.org/0000-0002-9876-8370
Lee, Hyun Chul(이현철)
Lim, Sung Kil(임승길)
Cho, Min Ho(조민호)
Cha, Bong Soo(차봉수) ORCID logo https://orcid.org/0000-0003-0542-2854
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.